Dexrazoxanum [Inn-Latin]

Dexrazoxanum [Inn-Latin] Brand names, Dexrazoxanum [Inn-Latin] Analogs

Dexrazoxanum [Inn-Latin] Brand Names Mixture

No information avaliable

Dexrazoxanum [Inn-Latin] Chemical_Formula

C₁₁H₁₆N₄O₄

Dexrazoxanum [Inn-Latin] RX_link

http://www.rxlist.com/cgi/generic2/dexrazoxane.htm

Dexrazoxanum [Inn-Latin] fda sheet

Dexrazoxanum_[Inn-Latin] FDA

Dexrazoxanum [Inn-Latin] msds (material safety sheet)

Dexrazoxanum_[Inn-Latin] MSDS

Dexrazoxanum [Inn-Latin] Synthesis Reference

No information avaliable

Dexrazoxanum [Inn-Latin] Molecular Weight

268.269 g/mol

Dexrazoxanum [Inn-Latin] Melting Point

191 - 197 ^oC

Dexrazoxanum [Inn-Latin] H₂O Solubility

Sparingly soluble

Dexrazoxanum [Inn-Latin] State

Solid

Dexrazoxanum [Inn-Latin] LogP

-2.135

Dexrazoxanum [Inn-Latin] Dosage Forms

Liquid; Powder for solution

Dexrazoxanum [Inn-Latin] Indication

For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.

Dexrazoxanum [Inn-Latin] Pharmacology

Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose.

Dexrazoxanum [Inn-Latin] Absorption

IV administration results in complete bioavailability.

Dexrazoxanum [Inn-Latin] side effects and Toxicity

Intraperitoneal, mouse LD₁₀ = 500 mg/kg. Intravenous, dog LD₁₀ = 2 gm/kg.

Dexrazoxanum [Inn-Latin] Patient Information